Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
CSPC Pharmaceutical Group ( (HK:1093) ) has provided an update.
CSPC Pharmaceutical Group has received approval from China’s National Medical Products Administration to conduct clinical trials for its high-concentration hydroxocobalamin hydrochloride injection, aimed at treating methylmalonic acidemia (MMA). This approval marks the first hydroxocobalamin injection approved in China for MMA, addressing a significant unmet medical need and potentially offering a new treatment option for patients with this rare metabolic disorder.
The most recent analyst rating on (HK:1093) stock is a Buy with a HK$6.80 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page.
More about CSPC Pharmaceutical Group
CSPC Pharmaceutical Group is a Hong Kong-based company operating in the pharmaceutical industry. It focuses on developing and manufacturing a range of pharmaceutical products, with a particular emphasis on innovative drugs and therapies.
Average Trading Volume: 214,314,790
Technical Sentiment Signal: Strong Buy
Current Market Cap: HK$88.55B
For detailed information about 1093 stock, go to TipRanks’ Stock Analysis page.